Location of Repository

Hyperthermia combined with chemotherapy - Biological rationale, clinical application, and treatment results

By Rolf-Dieter Issels

Abstract

There is substantial evidence from preclinical data that the antitumor cytotoxicity of selected chemotherapeutic agents either alone or combined with radiation can be enhanced by appropriate heat exposure (40-44 degrees C) of cells or tumor tissues. Based upon these results the integration of hyperthermia as an additional treatment modality, given simultaneously with systemic chemotherapy or in combination with radiochemotherapy, is currently tested at the clinic. Regional hyperthermia combined with chemotherapy or radiochemotherapy showed impressive results (phase II studies) at clinical relevant temperatures in locally advanced tumors of different entities in terms of objective response rate, local tumor control and relapse-free survival. Clinical protocols of well-designed phase III trials on combined treatment modalities integrating hyperthermia are rather limited but for some tumors confirm its clinical benefit. In general, the clinical approach to use hyperthermia has gained much more interest within in the field of medical oncology. One of the major reason is the substantial technical improvements made with the available commercial equipment for local or regional heating, especially in case of deep-seated lesions or systemic heating. Further testing of the potential of hyperthermia combined with chemotherapy or radiochemotherapy in prospective randomized trials are warranted. At this time, hyperthermia as an adjunct to conventional treatment strategies is recommended in the setting of clinical protocols. The results of prospective trials should answer the question for which types of local advanced or metastatic tumors hyperthermia becomes standard as part of a multi-modal treatment strategy.

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 1999
DOI identifier: 10.1159/000026986
OAI identifier: oai:epub.ub.uni-muenchen.de:16495
Provided by: Open Access LMU

Suggested articles

Preview

Citations

  1. (1992). Abravaya K: Transcriptional regulation of heat shock genes. A paradigm for inducible genomic responses.
  2. AJ: A review of microwave and RF applicators for localised hyperthermia;
  3. Arrhenius relationships from the molecule and cell to the clinic.
  4. (1994). BS: Cancer and the heat shock response.
  5. (1993). Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: A phase I-II study.
  6. (1993). D: A phase I clinical study of carboplatin and 41.8 °C whole body hyperthermia in cancer patients.
  7. (1993). Deep regional hyperthermia: Comparison between the annular phased array and the sigma-60 applicator in the same patients.
  8. (1994). Douple E: Hyperthermia and Oncology, vol 4. VSP
  9. (1996). F: Isolated limb perfusion with high-dose tumor necrosis factor-a in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial.
  10. (1996). FF: Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials.
  11. Hartl FU: Molecular chaperone functions of heat-shock proteins.
  12. (1993). Havers W: Regionale Hyperthermie mit systemischer Chemotherapie bei Kindern und Jugendlichen: Durchführbarkeit und klinische Verläufe bei 34 intensiv vorbehandelten Patienten mit prognostisch ungünstigen Tumorerkrankungen. Klin Pädiatr
  13. (1997). Helmerhorst TJM, Veenhof CHN: Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer
  14. Henle KJ: Arrhenius analysis of heat survival curves form normal and thermotolerant CHO cells. Radiat Res 1979;78:251–263.
  15. (1994). High-dose preoperative radiation and full thickness local excision: A new option for selected T3 distal rectal cancers.
  16. (1994). Hyperthermia and drug resistance;
  17. (1998). Hyperthermia for the treatment of patients with malignant germ cell tumors. A phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer
  18. (1994). Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res
  19. (1996). Ifosfamide, carboplatin, and etoposide (ICE) combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma.
  20. Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Hepatogastroenterology 1996;46:
  21. Issels R: Heat shock protein 72 on tumor cells. A recognition structure for NK cells.
  22. (1997). JA: Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients.
  23. (1994). JD: A new technological approach to radiant heat whole body hyperthermia. Cancer Lett
  24. (1992). Kuwano H: Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus – A prospective randomized trial.
  25. LF: Clinico-pathological features of prognostic significance in operable rectal cancer in 17 centres in the UK.
  26. (1992). McGuire WL: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res
  27. Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity;
  28. (1995). Metabolic status and reaction to heat of normal and tumor tissue; in Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy.
  29. (1995). Molecular and cellular mechanisms of hyperthermia; in Seegenschmiedt
  30. (1989). Nagle WA: Characterization of a cisplatinresistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia. Cancer Res
  31. (1998). Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) followed by surgery and radiation in primary and recurrent high-risk soft tissue sarcomas (HRSTS) of adults (updated report).
  32. (1994). Oshiumi Y: Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: A prospective randomized trial.
  33. (1990). Pathophysiological mechanisms of hyperthermia in cancer therapy; in Gautherie M (ed): Biological Basis of Oncologic Thermotherapy.
  34. (1995). PJM: Effect of hyperthermia on the cytotoxicity of 2’,2’-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells.
  35. (1998). PM: Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. A phase II clinical trial. Ann Surg
  36. (1987). Radiofrequency capacitive hyperthermia for deep-seated tumors. Cancer
  37. (1993). RT: Preoperative irradiation for unresectable carcinoma of the rectum. Surg Gynecol Obstet
  38. (1990). S: Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs.
  39. Samulski TV: Magnetic resonance thermometry during hyperthermia for human highgrade sarcoma.
  40. (1993). SL: Sensitivity of hyperthermia trial outcomes to temperature and time: Implications for thermal goals of treatment.
  41. (1995). SM for the European Society for Hyperthermic Oncology: Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet
  42. (1992). Song CW: Radiation and heat sensitivity of human T-lineage acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) clones displaying multidrug resistance (MDR).
  43. (1993). Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity.
  44. Srivastava PK: Immunotherapy of tumors with autologous tumorderived heat shock protein preparations.
  45. Sugimachi K: Hyperthermo-Chemo-Radiotherapy for patients with early carcinoma of the esophagus. Hepatogastroenterology 1993;40:217–221.
  46. (1987). Surgical strategies in locoregional recurrences of gastrointestinal carcinoma.
  47. Terminology in the description of drugradiation interaction.
  48. (1989). The current and potential role of hyperthermia in radiotherapy.
  49. Wilmanns W: Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study.
  50. (1991). Wilmanns W: Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: Updated report on 65 patients.
  51. Wilmanns W: Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: A pilot study.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.